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Cognitive impairment is a core feature of schizophrenia as
deficits are present in the majority of patients, frequently
precede the onset of other positive symptoms, persist
even with successful treatment of positive symptoms, and
account for a significant portion of functional impairment
in schizophrenia. While the atypical antipsychotics have
produced incremental improvements in the cognitive func-
tion of patients with schizophrenia, overall treatment
remains inadequate. In recent years, there has been an in-
creased interest in developing novel strategies for treating
the cognitive deficits in schizophrenia, focusing on amelio-
rating impairments in working memory, attention, and so-
cial cognition. Here we review various molecular targets
that are actively being explored for potential drug discov-
ery efforts in schizophrenia and cognition. These molecular
targets include dopamine receptors in the prefrontal cortex,
nicotinic and muscarinic acetylcholine receptors, the gluta-
matergic excitatory synapse, various serotonin receptors,




Schizophrenia is characterized by positive symptoms
such as delusions and hallucinations, negative symptoms
such as avolition and flat affect, and cognitive impair-
ments. Although Kraepelin,1 with his term ‘‘dementia
praecox,’’ characterized the relationship between cogni-
tive deficits and schizophrenia nearly a century ago, effec-
tive treatments for these deficits have not been developed.
Cognitive dysfunction is estimated to occur in 75%–
85% of patients with schizophrenia,2 often precedes the
onset of other symptoms,2 and persists even after other
symptoms have been effectively treated.3 Indeed, a meta-
analysis of cognitive deficits suggested that indices of cog-
nitive deficits are much better predictors of functional
outcome than indices from any other symptom domain.4
Furthermore, the severity of cognitive deficits is predictive
of poorer medication compliance,5 overall treatment ad-
herence,6 and increased tendency for relapse in first-epi-
sode patients.7
Until recently, antipsychotic drug development in
schizophrenia has focused mainly on developing drugs
that reduce the positive symptoms of schizophrenia,8
and indeed, all the current medications appear to be sim-
ilar in efficacy for reducing positive symptoms in typical
patients with schizophrenia.9,10 In a recent meta-analysis,
patients treated with typical antipsychotics were actually
shown to have small but detectable improvements in sev-
eral cognitive domains11; however, due to extrapyramidal
side effects, many patients are also treated with anticho-
linergic agents that are well known to impair memory12
and global cognitive ability.13 In addition, there is some
evidence for the superiority of atypical antipsychotics,
such as olanzapine and risperidone, over typicals in im-
proving cognitive performance,14–16 though the benefits
are relatively small and have not been consistently repro-
duced.17 Overall, the widespread use of the atypical anti-
psychotics has likely offered some cognitive benefit for
patients with schizophrenia,18 though significant deficits
persist, suggesting a need for directive treatments for en-
hancing cognition.
Due to the continued need for improved treatment of the
cognitive impairments in schizophrenia, Wayne Fenton
spearheaded the National Institutes of Mental Health’s
joint academic and industry initiative termed MATRICS
(Measurement and Treatment Research to Improve Cog-
nition in Schizophrenia) to facilitate the development of
better treatments targeted at cognition.19 An initial
MATRICS conference (http://www.matrics.ucla.edu)
identified 7 primary cognitive domains that are crucial
for developing targets for the treatment of cognition in
schizophrenia. These domains included working memory,
speedofprocessing, verbal learningand memory, attention
and vigilance, reasoning and problem solving, visual learn-
ing and memory, and social cognition.20–22 An additional
MATRICS conference (http://www.matrics.ucla.edu)
identified pharmacologic strategies that hold promise for
the treatment of impaired cognition in schizophrenia.
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The primary molecular targets identified included dopa-
mine receptors in the prefrontal cortex, nicotinic and
muscarinic acetylcholine receptors, the glutamatergic
excitatory synapse, various serotonin receptors, and the
c-aminobutyric acid (GABA) system. Below, we review
many of the molecular targets being studied for potential
drug development strategies aimed atenhancing cognition,
both generally and specifically in schizophrenia (table 1).
Cholinergic Targets
Acetylcholine is known to play an important role not
only in motor function but also in various domains of
cognition, particularly attention, learning, and mem-
ory.23 Indeed, cholinergic dysfunction has been shown
to be central to the pathophysiology of Alzheimer’s dis-
ease and has also been postulated to contribute to the
cognitive deficits of various neuropsychiatric disorders,
including schizophrenia.23 The basal cholinergic complex
sends widely diffuse afferents through 2 projections: the
septohippocampal and the nucleus basalis of Meynart
cortical pathways.24 The septohippocampal pathway is
important in working memory processes through hippo-
campal storage of intermediate-term memory,25,26
whereas the nucleus basalis of Meynart cortical pathway
is involved in reference memory through long-term infor-
mation storage in the neocortex.27,28 Additionally, a role
for acetylcholine in the processes of attention has been
demonstrated in rats and monkeys.29 Pharmacologically,
anticholinergic drugs, like scopolamine, produce learning
impairments in healthy subjects similar to those of per-
sons with dementia,30 while cholinomimetic drugs, like
physostigmine, can significantly enhance the memory
functions of healthy individuals.30,31
Although the degeneration of cholinergic neurons in the
basal forebrain and the associated loss of cerebral neuro-
transmission that is seen in Alzheimer’s disease are absent
in schizophrenia,32,33 there is evidence of decreased nico-
tinic34 and muscarinic35 acetylcholine receptors in the cor-
tex and hippocampus of individuals with schizophrenia.
Interestingly, in patients with schizophrenia, decreased ac-
tivity of choline acetyltransferase, a biosynthetic enzyme
for acetylcholine production, was correlated with poorer
cognitive functioning as measured by the Clinical Demen-
tia Rating.33 In addition, some of the atypical antipsy-
chotics, but not typical antipsychotics, can increase the
release of acetylcholine in the prefrontal cortex, possibly
contributing to their modest enhancement of cognition in
schizophrenia.36 Thus, various targets within the cholin-
ergic system are being investigated as potential enhancers
of cognition in schizophrenia.
Cholinesterases
Cholinesterase inhibitors, such as donepezil and rivastig-
mine, are currently the main pharmacologic approach to






a Dihydrexidine Positive proof-of-
concept trials
D4 antagonists Sonepiprazole Ineffective in acute
schizophrenia
D4 agonists A-412997 n/a
COMT inhibitors Tolcapone Improved cognition
in Parkinson’s disease
5-HT2A antagonists M100907 Modest efficacy in
acute schizophrenia
5-HT1A agonists Tandospirone Mixed results
5-HT1A antagonists WAY100635 n/a
5-HT4 agonists Tegaserod Recently withdrawn
from market in IBSb
5-HT6 antagonists SB-271046 n/a


















M4 agonists No selective
ligands
n/a
M5 antagonists No selective
ligands
n/a
NMDA enhancers Glycine Multiple small trials,
mostly positive
GlyT inhibitors Org-24598 Positive proof-of-
concept trials
Ampakines CX-516 Mixed proof-of-concept
trials
mGluR2/3 agonists Unknown Positive proof-of-
concept trial reported
mGluR5 agonists CDPPB n/a
a2-adrenergic
antagonists
Guanfacine Positive small trials
GABAA (a2)
agonists





Sigma agonists No selective
ligands
n/a
Note: D, dopamine; n/a, clinical evidence not available to date;
COMT, catechol-O-methyltransferase; 5-HT, serotonin; IBS,
irritable bowel syndrome; DMXB-A, 3-2,4-dimethoxybenzylidene
anabaseine; M, muscarinic; NMDA, N-methyl-D-aspartate; GlyT,
glycine transporter; mGluR, metabotropic glutamate receptor;
GABA, c-aminobutyric acid.
aThe term ‘‘agonist’’ is used here to refer to agonists, partial
agonists, and positive allosteric modulators.
bwithdrawn due to increase in adverse cardiovascular events.
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the treatment of Alzheimer’s disease and have been
shown to slow the cognitive decline in this neurodegen-
erative disease.37 As such, it has been proposed that
cholinesterase inhibitors may also be useful in the treat-
ment of the cognitive dysfunction in schizophrenia.38
Acetylcholinesterase and butyrylcholinesterase are pres-
ent in a wide variety of tissues and are broadly distributed
in the brain. Inhibition of cholinesterases increases the
synaptic concentration of acetylcholine, thereby enhanc-
ing and prolonging the action of acetylcholine on both
muscarinic and nicotinic receptors. Therefore, cholines-
terase inhibitors act as indirect cholinergic agonists at
muscarinic and nicotinic receptors.
Following the administration of atypical antipsychotic
treatment, cholinesterase inhibitors can increase the con-
centration of acetylcholine in the medial prefrontal cortex
by 2- to 3-fold36 and have been demonstrated to produce
some functional normalization of brain activity during
verbal fluency task performance of schizophrenic patients
characterized by a significant increase in frontal lobe and
cingulate activity on functional magnetic resonance imag-
ing (fMRI).39 As such, in recent years there have been
multiple small randomized controlled trials of cholines-
terase inhibitors in patients with schizophrenia, though
results have been disappointing and inconsistent.40 It
has been suggested that the lack of consistent effects of
cholinesterase inhibitors may be due to the high rate of
cigarette smoking among patients with schizophrenia41
and subsequent desensitization of nicotinic receptors,42
thus rendering increased acetylcholine levels ineffective.43
Indeed, galantamine, an acetylcholinesterase inhibitor
that is also an allosteric potentiator of a7 nicotinic recep-
tors,44,45 does not cause a7 receptor desensitization and
has been shown to enhance cognitive functioning of
schizophrenic patients in a 4-week double-blind placebo
controlled trial.46 Interestingly, galantamine produced
cognitive enhancement in schizophrenic patients despite
the fact that all the patients smoked at least 10 cigarettes
per day.46 Unfortunately, despite these initial positive
findings, subsequent results with galantamine have
been mixed.47–49 Thus, while pure cholinesterase inhibi-
tors may be of minimal benefit for enhancing cognition
in patients with schizophrenia, possibly due to desensiti-
zation of their a7 nicotinic receptors from cigarette smok-
ing, further study may be warranted with combined
acetylcholinesterase inhibitors and allosteric potentiators
of the nicotinic receptor in schizophrenia. However, it is
likely that selective agents at various nicotinic and mus-
carinic receptors may be a more effective approach to de-
veloping drugs for treatment of the cognitive impairment
in schizophrenia.
Nicotinic Receptors
It is well known that the smoking rates in individuals with
schizophrenia are significantly higher than in the general
population, and some have suggested that these individ-
uals may be ‘‘self-medicating’’ with nicotine.50,51 Indeed,
nicotine administration has been shown to improve var-
ious measures of cognition that may ease some of the side
effects of antipsychotic medications.51 For example, in
patients with schizophrenia, a nicotine transdermal patch
could dose dependently reverse haloperidol-induced
impairments in working memory, attention, and reaction
time52 and has been shown to reduce haloperidol-induced
bradykinesia and rigidity compared with a placebo
patch.53 However, other studies have been mixed.54 Inter-
estingly, in one study,55 some of the modest effects of cig-
arette smoking on clinical and cognitive outcome
measures could also be improved by smoking denicoti-
nized cigarettes, suggesting that nonnicotine components
of cigarette smoke may also contribute.55 Overall, while
research on nicotinic treatment of individuals with
schizophrenia has shown that, in single administrations,
nicotine improves some aspects of cognition, additional
administrations are not effective due to rapid desensitiza-
tion of nicotinic receptors.42 Thus, considerable research
is exploring the potential use of nicotinic agents, partic-
ularly partial agonists and allosteric modulators at var-
ious nicotinic receptor subunits that would be less
likely to cause rapid receptor desensitization.
Nicotinic acetylcholine receptors are ionotropic recep-
tors with a pentameric structure composed of alpha (a2 to
a9) and beta (b2 to b4) subunits and are expressed at high
levels in the hippocampus, cortex, striatum, and thala-
mus.34,56 The 2 most prevalent nicotinic receptors are
the a4b2, which is a high-affinity receptor, and the a7,
which is a low-affinity nicotinic receptor, both of which
have been shown to have reduced numbers in patients
with schizophrenia.34,56 In addition, functional polymor-
phisms exist in the promoter region of the a7 receptor that
have shown genetic linkage in schizophrenia.57,58
The a7 nicotinic receptor subtype is a highly studied tar-
get for the development of drugs for cognitive enhance-
ment. Studies in rodents have shown that antagonists
at the a7 nicotinic receptor induce sensory gating deficits
similar to those seen in schizophrenia,59 a hippocampal
phenomenon manifested as an inability to attend appro-
priately to sensory stimuli.60 Sensory gating deficits may
strongly impact cognitive performance, and it has been
shown that smoking transiently normalizes these sensory
gating deficits.60 In addition, agonists at a7 receptors such
as 3-2,4-dimethoxybenzylidene anabaseine (DMXB-A)
can normalize the auditory gating deficits in rodents.61
Moreover, DMXB-A had a positive effect on a cognitive
battery in a small proof-of-concept trial in humans,62 and
additional clinical trials of a7 receptor agonists are under-
way. However, there is concern that long-term use of a7
agonists may induce the desensitization of nicotinic recep-
tors, leading to a limited duration of efficacy.63 Thus,
further development of a7 receptor partial agonists (eg,
GTS-21) and allosteric potentiators (eg, galantamine)
that induce minimal receptor desensitization is warranted.
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In addition to a7 receptors, it has been suggested that
a4b2 nicotinic receptors are involved in cognition.
64 In-
deed, a4b2 receptors are considered to represent more
than 90% of the high-affinity nicotine-binding sites in
the rat brain,65 and decreased levels of a4b2 receptor
binding have been found in the hippocampus of patients
with schizophrenia.56 Furthermore, agonists of a4b2
receptors, such as RJR2403 and SIB-1553A, can produce
a significant and long-lasting improvement of memory in
rats and monkeys.66–68 Additionally, a4b2 agonists have
been shown to stimulate the release of dopamine, norepi-
nephrine, and acetylcholine in the hippocampus and
frontal cortex in rats.66 Thus, nicotinic a4b2 receptor ago-
nists may be of therapeutic benefit for the treatment of
the cognitive deficits in schizophrenia by several mecha-
nisms. In addition to a7 and a4b2 receptors, other nico-
tinic receptors, such as a3- and a6-containing receptors,
may be involved in cognitive performance; however,
studies are limited due to the lack of selective agonists
and antagonists for these receptors.
Muscarinic Receptors
In addition to the ionotropic nicotinic receptors, numerous
studies have implicated metabotropic muscarinic acetyl-
choline receptors in schizophrenia. Muscarinic receptors
are G protein–coupled receptors69 found widely through-
out thecentralnervoussystemonbothcholinergicandnon-
cholinergic cells where they function as both autoreceptors
and heteroreceptors.70–72 Of the 5 genetically distinct sub-
typesofmuscarinicreceptors (M1–M5), theM1 receptorhas
been most closely linked to cognition and schizophrenia.73
Indeed, theM1 receptorsubtype is themostabundantof the
muscarinic receptors in forebrain and hippocampus,74,75
brain regions crucial to normal cognitive functions. In ad-
dition, decreased M1 receptor binding has been reported in
postmortem studies of the prefrontal cortex, hippocampus,
and striatum from patients with schizophrenia,76–78 that is,
importantly, not due to chronic antipsychotic treat-
ment.35,77,79 Interestingly,M1 receptor–deficientmicedem-
onstrate deficits in working memory and remote reference
memory indicative of impairedhippocampal-cortical inter-
actions.80 Together, these results suggest that alterations in
centralM1receptorsmayhavearoleinthepathophysiology
of schizophreniaand that M1 receptor agonists may beben-
eficial in treating schizophrenia, particularly the cognitive
impairments.73
Action at M1 receptors has been proposed to be a
major contributor to the cognition-enhancing effects of
clozapine,81 despite the fact that clozapine is an exceed-
ingly weak partial agonist at M1 and other muscarinic
receptors.73,82 Thus, attention has focused on various
clozapine metabolites including clozapine-N-oxide and
N-desmethylclozapine (NDMC). Clozapine-N-oxide is
inactive while NDMC has actions at many receptors
(http://pdsp.med.unc.edu/pdsp.php).82 Interestingly,
NDMC is the major active metabolic of clozapine and
has been reported to be a potent M1 agonist that prefer-
entially binds to M1 receptors vs clozapine,
83 although
more comprehensive studies fail to demonstrate selectiv-
ity of NDMC for M1 receptors.
84 In addition, NDMC
has high affinities for 5-HT2A and 5-HT2C receptors
and is a partial agonist at D2, D3 receptors
85,86 and d-opi-
oid receptors,87 suggesting that this metabolite of cloza-
pine may have antipsychotic and cognition-enhancing
properties via a number of mechanisms. Furthermore,
NDMC, but not clozapine, increases release of dopamine
and acetylcholine in the prefrontal cortex and the hippo-
campus88 and potentiates NMDA receptor activity in the
hippocampus.83 Thus, the cognitive enhancement ob-
served with clozapine could actually be due to its metab-
olite NDMC via an uncertain mechanism.
Indeed, NDMC (ACP-104) and other M1 receptor ago-
nists are in clinical trials as potential treatments of the
cognitive dysfunction in schizophrenia. Xanomeline, a
nonselective M1 and M4 muscarinic agonist with potent
actions at a variety of additional nonmuscarinic receptors
including 5-HT1A and 5-HT2A receptors,
89 improved cog-
nition and psychotic-like symptoms in Alzheimer’s dis-
ease.90 In addition, monotherapy with xanomeline
resulted in an improvement of positive symptoms and
cognitive function in 20 subjects with schizophrenia91
but was discontinued due to poor tolerability.92 The rel-
atively nonselective actions of xanomeline and NMDC
at a number of receptors (http://pdsp.med.unc.edu/
pdsp.php) should engender caution among schizophrenia
researchers for embracing positive data from xanomeline
and NMDC studies as being specifically indicative of
a role for M1 receptors in schizophrenia.
Overall, evidence suggests that M1 receptor agonists
could be useful in treating various symptom domains
in schizophrenia, though the roles of the other muscarinic
receptor subtypes are less clear. M5 receptors, for exam-
ple, may be relevant to schizophrenia as they are located
in the brainstem and midbrain, where they have an effect
on dopamine release.93 Indeed, xanomeline is also an an-
tagonist at M5 receptors, suggesting that blockade of M5
may be involved in the benefits seen with xanomeline.94
In addition, M4 receptor knockout mice have impair-
ments of cognitive performance and elevated levels of do-
pamine in the nucleus accumbens, suggesting a potential
role for M4 receptor agonists in treating both the positive
and cognitive symptoms of schizophrenia.95,96 As selec-
tive agonists at muscarinic receptor subtypes have been
difficult to develop, positive allosteric modulators are
also being explored as potential therapeutic agents.
Glutaminergic Targets
Glutamate is the primary excitatory neurotransmitter for
approximately 60% of the neurons in the mammalian
brain, including all cortical pyramidal neurons,97 and
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plays a principal role in modulating long-term potentia-
tion, a likely key cellular mechanism for learning and
memory.98,99 Glutamate mediates fast excitatory postsyn-
aptic potentials by acting on 3 ionotropic receptors, which
are differentiated based upon sensitivity to the synthetic
glutamate derivatives N-methyl-D-aspartate (NMDA),
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA), and kainate.100 In addition, glutamate
exerts slower modulatory effects by acting on various
G protein–coupled metabotropic glutamate receptors
(mGluRs).101 For example, mGluR2 and mGluR3 recep-
tors modulate the release of glutamate, whereas the
mGluR5 receptor potentiates the duration of NMDA re-
ceptor–dependent excitatory postsynaptic potentials.102
It has been hypothesized for decades that some defi-
ciency in NMDA function might play a role in the patho-
physiology of schizophrenia.103 Since the 1950s, the
NMDA receptor antagonists phencyclidine (PCP) and
ketamine were known to produce a large range of schizo-
phrenia-like symptoms including psychotic symptoms,
negative symptoms, and cognitive dysfunction,103–105
and it has been suggested that augmenting NMDA recep-
tor activity may have therapeutic potential in schizophre-
nia.100 Indeed, some of the atypical antipsychotics, but
not typical antipsychotics, have been shown in preclinical
models to reverse the effects of ketamine and PCP,106–109
presumably through indirect activation of NMDA recep-
tors mediated by other neurotransmitter systems.83 It is
also important to note that a competing hypothesis sug-
gests that a hyperactivity of glutamatergic neurotransmis-
sion is involved in the psychopathology of schizophrenia,
leading to seemingly contradictory pharmacologic
approaches being explored.100 Indeed, glutamatergic exci-
totoxicity is thought to be a factor in the neurodegenera-
tion of Alzheimer’s disease110 and a weak NMDA receptor
antagonist, memantine, has shown efficacy in slowing cog-
nitive decline in moderate to advanced Alzheimer’s dis-
ease.111 Thus, the glutamate system, especially its
NMDA-dependent components, is complex, and while
small increases in NMDA-dependent glutamate neuro-
transmissionmightbecognitivelyenhancing, toomuchac-
tivation may result in neurodegeneration.Fortunately, the
glutamatergic excitatory synapse offers multiple targets
for drug development to provide the precise level of en-
hancement to improve cognition without excitotoxicity.
Thus, we briefly review below various approaches being
explored for modulating NMDA receptor neurotransmis-
sion and discuss approaches aimed at other glutamatergic
mediators.
NMDA Receptors
NMDA glutamate receptors are ligand-gated ion chan-
nels with a primary glutamate-binding site and an allo-
steric glycine-binding site.100 Interestingly, the opening
of the NMDA channel appears to require both glutamate
and glycine binding, with glycine binding affecting chan-
nel open time and desensitization rate but not inducing
channel opening itself.100 In addition, NMDA receptorac-
tivity can be allosterically modulated by multiple other
substances, including Mg2þ, polyamines, and protons.112
Thus, while direct agonists of the glutamate-binding site of
the NMDA receptor may not be clinically feasible due to
the risk of excess excitation and neurotoxicity, the alloste-
ric sites on the NMDA receptor complex, particularly the
glycine-binding site, are promising targets for drug devel-
opment. Indeed, chronic treatment of rodents with glycine
has not been found to induce excitotoxicity.113,114
Compounds that target the glycine site of the NMDA
receptor complex have been studied in multiple small
clinical trials. These include glycine115 and D-serine,116
which are endogenous agonists at the glycine site of
the NMDA receptor complex; D-alanine; and D-cycloser-
ine, an antituberculosis drug that also binds to the glycine
modulatory site where it functions as a partial agonist.117
In most of these studies, the test compound was admin-
istered along with either a typical or atypical antipsy-
chotic, and there appears to be significant effects at
reducing negative symptoms and cognitive impairment
in patients with schizophrenia.118 Of the 4 agents, D-cy-
closerine has been the least efficacious, likely due to it be-
ing a partial agonist that acts as an antagonist at high
doses. Interestingly, when used concurrently with cloza-
pine, glycine119 and D-serine120 have been reported to be
ineffective while D-cycloserine seemed to worsen symp-
toms,121 possibly because clozapine may already enhance
glycine and glutamate neurotransmission. Overall, ago-
nists at the glycine allosteric site of the NMDA glutamate
receptor hold promise in the treatment of the negative
and cognitive symptoms of schizophrenia, possibly as
an augmentation of currently existing antipsychotics.
A potential limitation of targeting the glycine modula-
tory site is that the glycine site is probably half-saturated
during physiologic conditions, suggesting that treatments
targeting the glycine site would theoretically only be able
to effectively double NMDA neurotransmission.118 In
addition, both glycine and D-serine must be given at
gram-level doses to significantly elevate central nervous
system levels, and attempts to modify glycine or D-serine
to produce synthetic glycine-site agonists, have, thus far,
been unsuccessful. Thus, indirect approaches to activate
NMDA receptors are being explored, such as increasing
extracellular glycine and glutamate and by modulating
AMPA receptors and mGluRs.
Glycine Transporters
An indirect approach being explored to boost NMDA
activity via the glycine allosteric site is to increase synap-
tic glycine by inhibiting the glycine transporter. The gly-
cine transporters, GlyT1 and GlyT2, have been identified
on both neuronal and glial cells in the central nervous
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system, where they are suggested to control the extracel-
lular concentration of glycine.122 Thus, blockade of gly-
cine transporters is predicted to increase extracellular
glycine and thus enhance NMDA receptor neurotrans-
mission. Indeed, preclinical data suggest that inhibition
of glycine reuptake represents a feasible approach to
enhance NMDA receptor activity and possibly be thera-
peutic in schizophrenia.100 For example, selective, high-
affinity inhibitors of the glycine transporter, including
Org-24598, N-[3-(4#-fluorophenyl)-3-(4#-phenylphenox-
y)propyl] sarcosine, and SSR-504734, have been found
to reverse PCP-induced hyperactivity and dopaminergic
hyperreactivity in rodents.123,124 Furthermore, the gly-
cine transport inhibitor glycyldodecylamide attenuated
PCP-induced hyperactivity more potently than adminis-
tration of glycine.125,126
Clinical trials to date, however, have only studied the
low-potency glycine transport inhibitor sarcosine (N-
methyl glycine). In a clinical trial of sarcosine added to
the stable antipsychotic regimen of patient with schizo-
phrenia, there was a highly significant reduction in neg-
ative symptoms, along with smaller but significant
reductions in positive and cognitive symptoms.127 Inter-
estingly, a subsequent study with patients on clozapine
found no improvement of symptoms with the addition
of sarcosine, a result similar to studies with the
NMDA glycine site agonists.128 These results strongly
suggest a role of glycine transport inhibitors in the treat-
ment of schizophrenia, though results of trials with selec-
tive, high-potency inhibitors are anticipated.
AMPA/Kainate Receptors
Another glutamatergic approach to drug development
for cognitive enhancement in schizophrenia has been
the development of compounds that stimulate AMPA
and kainate glutamate receptors. AMPA and kainate
receptors mediate the majority of the fast glutamatergic
signaling in the brain, and AMPA receptors work heavily
in concert with NMDA receptors.100 AMPA receptors
provide the primary depolarization necessary to activate
NMDA receptors, while NMDA receptors are required
for proper incorporation of AMPA receptors into the
postsynaptic membrane, a process involved in synaptic
plasticity.129 Thus, activation of AMPA receptors is
likely critically important for learning and memory; how-
ever, direct AMPA agonists are unlikely to be therapeu-
tically useful as AMPA receptors rapidly desensitize after
stimulation.130
In an attempt to avoid desensitization of AMPA recep-
tors, allosteric potentiators of AMPA receptor function,
a class of compounds termed ampakines, are being stud-
ied as potential treatments for enhancing cognition in
schizophrenia.131,132 Indeed, ampakines have been shown
to enhance glutamatergic transmission and facilitate
long-term potentiation in rodents.133,134 Furthermore,
ampakines improve performance in rodents on a variety
of memory tasks including spatial mazes135,136 and
learned fear137 and have been shown to be effective in re-
ducing age-associated memory deficits in rats.138 In a clin-
ical trial of schizophrenia patients on clozapine,
coadministration of the ampakine CX-516 yielded signif-
icant improvements in memory and attention;139 how-
ever, a trial of CX-516 as monotherapy in
schizophrenia showed no clear beneficial effects.140 Im-
portantly, higher potency ampakines are currently under
clinical development as both monotherapy for schizo-
phrenia and adjunctive treatment for cognitive dysfunc-
tion, though results of trials are not yet available. A
higher potency ampakine, farampator, has been tested
in healthy elderly volunteers and improved short-term
memory but appeared to impair episodic memory,141
and thus, it remains unclear if modulation of AMPA
receptors has therapeutic value in the treatment of the
cognitive dysfunction in schizophrenia although this is
a highly active area of current research.
Metabotropic Glutamate Receptors
Agents acting at mGluRs, which serve to regulate gluta-
matergic neurotransmission both pre- and postsynapti-
cally, are currently in preclinical development for
treatment of the cognitive dysfunction in schizophrenia.
There are 8 subtypes of mGluRs (mGluR1–8) which are
categorized into 3 groups according to their second mes-
senger-coupling and ligand-binding profiles with group I
receptors (mGluR1 and mGluR5) primarily being stud-
ied for cognitive enhancement in schizophrenia.102
Group I receptors, particularly mGluR5, function pre-
dominantly to potentiate both presynaptic glutamate re-
lease and postsynaptic NMDA neurotransmission,142
and mGluR5 receptors show significant colocalization
with NMDA receptors in cortical pyramidal neurons.143
Together, these findings suggest that mGluR5 agonism
may enhance NMDA activity and improve memory
and cognition.142 Indeed, selective mGluR5 agonists
were found to inhibit PCP-induced dopamine release
in the rodent prefrontal cortex.144 Direct mGluR5 ago-
nists, however, are likely to induce receptor desensitiza-
tion limiting their therapeutic usefulness. Thus, selective
allosteric potentiators of mGluRs have recently been
developed and hold promise as therapeutic agents.145,146
Indeed, preliminary positive results with an mGluR2/3





Dopamine projections to the prefrontal cortex compris-
ing the mesocortical dopamine system are essential for
normal cognition.147,148 Thus, it has been hypothesized
1105






/schizophreniabulletin/article-abstract/33/5/1100/1896958 by guest on 21 July 2020
that decreased dopaminergic neurotransmission in the
prefrontal cortex contributes to the cognitive deficits ob-
served in schizophrenia, especially those related to exec-
utive functions and working memory.149–151 Indeed,
postmortem and in vivo imaging studies have linked
prefrontal dopamine dysfunction to cognitive impair-
ment,151,152 and various studies have demonstrated
that direct and indirect dopamine agonists can improve
prefrontal cortex cognitive functions in humans.153,154
However, it seems that precise regulation of prefrontal
dopaminergic tone is essential as, in addition to insuffi-
cient dopamine, excessive prefrontal dopamine (eg,
resulting from acute stress) may be deleterious to cogni-
tion.155–157 Thus, dopamine function in the prefrontal
cortex seems to follow an ‘‘inverted-U’’ dose-response
curve whereby increases or decreases from an optimal
level result in cognitive impairment.158 Additionally, in-
direct dopamine agonists could potentially exacerbate
psychosis by increasing neurotransmission at mesolimbic
dopamine D2 receptors.
D1 Receptors
Dopamine D1 receptors are expressed at high levels on
the distal dendrites of pyramidal neurons in the prefron-
tal cortex that are thought to be involved in working
memory processes.158,159 Indeed, evidence suggests an
important role of dopamine D1 receptors in the cognitive
dysfunction of schizophrenia.138 For example, there is
a decreased level of D1 receptor–like binding in the pre-
frontal cortex of drug-naive patients with schizophrenia
as measured with positron emission tomography imag-
ing, and this decrease was found to be correlated with
the severity of negative symptoms and cognitive dysfunc-
tion but not with the severity of positive symptoms.160 In
addition, in nonhuman primates, chronic blockade of D2
receptors results in a downregulation of D1 receptors in
the prefrontal cortex and consequently produces severe
impairments in working memory.161 This downregula-
tion of D1 receptors may explain why long-term treat-
ment with typical antipsychotics can contribute to the
cognitive dysfunction in schizophrenia. Thus, significant
efforts are underway to examine the possible role of D1
receptor agonists in treating cognitive dysfunction in
schizophrenia. Indeed, low doses of selective D1 agonists,
such as dihydrexidine, A77636, and SKF81297, have
cognition-enhancing actions in nonhuman primates,162–164
and short-term administration of the D1 selective agonist,
ABT-431, reversed the cognitive deficits in monkeys trea-
ted chronically with a D2 receptor antagonist.
161
Although novel compounds that, directly or indirectly,
stimulate D1 receptors may be of immense value in treat-
ing cognitive deficits in schizophrenia, several potential
pitfalls may need to be overcome. First, D1 receptor ac-
tivity follows the ‘‘inverted-U’’ dose-response curve,
where either too little or too much D1 stimulation impairs
working memory.158 In addition, chronic treatment with
a D1 agonist may actually lead to the downregulation of
D1 receptors which could, potentially, worsen cognition
in the long term. Thus, an optimized level of D1 receptor
activation at the apex of the ‘‘inverted-U’’ may be re-
quired to obtain maximal cognitive benefits,157 which
may be accomplished by partial agonists or an intermit-
tent pattern of administration.161,165 An additional ob-
stacle is the powerful hypotensive effects of direct-
acting D1 agonists on peripheral D1 receptors,
166 which
may necessitate the use of indirect D1-activating agents
such as catechol-O-methyltransferase (COMT) inhibitors
(see below).
D4 Receptors
The high affinity of clozapine for dopamine D4 receptors
led to speculation that D4 receptors may be clozapine’s
‘‘magic receptor.’’167 Clinical trials of selective D4 antag-
onists, however, have not demonstrated any appreciable
efficacy in the treatment of acute schizophrenia,168–170
though it is possible that D4 receptor blockade in collab-
oration with action at other neurotransmitter receptors
may be clinically beneficial. Indeed, studies of the phys-
iological roles for the D4 receptor are finding that D4
receptors may play an important role in impulsivity
and working memory.171
The mechanism by which D4 blockade could improve
cognition is not fully known,172 though D4 receptors are
present on both pyramidal neurons and GABA-produc-
ing interneurons in the prefrontal cortex and hippocam-
pus,173 areas important for cognitive function. Studies
have demonstrated that activation of D4 receptors
decreases NMDA receptor activity in the hippocam-
pus174 and inhibits glutamatergic signaling in the prefron-
tal cortex.175 Additionally, D4 receptor knockout mice
show enhanced activity of cortical pyramidal neurons,
an effect mimicked in wild-type mice by administration
of the D4 antagonist PNU-101387G.
175 Together, these
results suggest that D4 antagonism may be a valuable ap-
proach to improve cognition in schizophrenia. Indeed,
the D4 antagonist NDG96-1 was reported to reverse
PCP-induced deficits in object retrieval tasks in mon-
keys,172 and another D4 antagonist, PNU-101387G, re-
versed deficits in the delayed response task induced by
the pharmacologic stressor FG7142 (a benzodiazepine
inverse agonist).176 Interestingly, PCP-induced cognitive
deficits are exacerbated by haloperidol, suggesting that
strong blockade of other dopamine receptors may
counter the beneficial effects of D4 blockade on cognitive
functioning.172
Seemingly contradictory evidence also suggests that D4
receptor agonists may improve cognitive function. For
example, the selective D4 agonist A-412997 showed
dose-dependent improvement in social recognition in
rats, a model of short-term memory,177 and the D4
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agonist PD168077 was shown to facilitate memory con-
solidation of an inhibitory avoidance learned response in
mice.178 These effects have been hypothesized to be due
to D4 receptor modulation of inhibitory GABAergic sig-
naling in the prefrontal cortex.179 Indeed, the D4 agonist
PD168077 reduces GABAA inhibitory currents in pyra-
midal neurons, which could be blocked by the D4 antag-
onist L-745870 as well as clozapine.179 Thus, in contrast
to D4 antagonist–induced enhancement of NMDA cur-
rents in the hippocampus, D4 agonists may suppress
GABAA inhibitory currents in the prefrontal cortex
and thereby indirectly enhance cortical excitability.
Taken together, D4 receptor–selective agents may be
valuable in the treatment of the cognitive deficits in
schizophrenia, though a balance between D4 receptor
modulation of prefrontal GABAA and hippocampal
NMDA receptors may be necessary.
Catechol-O-methyltransferase
COMT is a postsynaptic enzyme that methylates and
thereby deactivates synaptically released catecholamines,
particularly dopamine.180 Historically, monoamine oxi-
dase was considered the primary enzyme for the initial
deactivation of synaptic dopamine,181 though mounting
evidence suggests that COMT may be especially impor-
tant for the breakdown of dopamine, particularly in the
prefrontal cortex.182 For example, COMT knockout
mice show increased baseline levels of dopamine, but
not other catecholamines such as norepinephrine, specif-
ically in the frontal cortex.183 In addition, the COMT
knockout mice also showed enhanced memory perfor-
mance,183 suggesting a potential role of COMT inhibition
in improving cognition. Indeed, a selective, reversible in-
hibitor of COMT, tolcapone, has been reported to im-
prove working memory in rodents184 and has been
shown to improve cognitive dysfunction in patients
with advanced Parkinson’s disease,185 though use is lim-
ited due to a risk of liver failure.186 Other COMT inhib-
itors are currently being investigated for treatment of the
cognitive dysfunction in schizophrenia.
Interestingly, a common single nucleotide polymor-
phism in the gene encoding COMT, Val158Met, results
in the transcription of a variant of the COMT enzyme
with approximately 40% less enzymatic activity in
humans.187 The reduced COMT enzymatic activity asso-
ciated with the Met variant presumably results in greater
availability of dopamine in the prefrontal cortex and, thus,
may improve cognition, hypotheses supported by findings
from the COMT knockout mice,183 and an fMRI study in
humans.188 Furthermore, the COMT locus at chromo-
some 22q11 has been identified as a susceptibility locus
for schizophrenia in several linkage studies189,190 and 2
meta-analyzes,189,191 though this remains controver-
sial.192–194 However, accumulating evidence predicts
that patients with schizophrenia who have the Met allele
may have improved cognitive response to clozapine.195 In-
terestingly, a recent proof-of-concept experiment in
normal human subjects treated with tolcapone demon-
strated significant improvements on measures of executive
function and verbal episodic memory in individuals with
a Val/Val genotype but a diminished performance of indi-
viduals with the Met/Met genotype.196 Thus, overall, the
potential of pharmacologic inhibition of COMT in the
long-termtreatmentof thecognitivedysfunctioninschizo-
phrenia remains to be determined.
Serotonergic Targets
5-HT2A Receptors
5-HT2A receptors are particularly abundant in the pyra-
midal neurons from cortical layer V,197 where they have
been described to colocalize with NMDA glutamate
receptors,198,199 suggesting a role in modulating cognitive
functions. Indeed, studies have demonstrated that 5-
HT2A receptors interact with postsynaptic density pro-
tein 95, a protein involved in anchoring NMDA receptors
to postsynaptic densities,200 and it has been suggested
that activation of 5-HT2A receptors increases the release
of glutamate onto pyramidal cells.201 Interestingly, the
selective 5-HT2A receptor antagonist M100907 blocked
the cognition-impairing effects of MK-801, an NMDA
receptor antagonist.202,203 Similar findings have been
reported for another 5-HT2A antagonist AC-90179.
204
Taken together, these studies suggest an intimate associ-
ation between NMDA and 5-HT2A receptors and imply
that drugs with potent 5-HT2A antagonistic actions may
prove beneficial at improving cognition in schizophrenia,
perhaps by normalizing NMDA receptor functioning.203
In addition, 5-HT2A receptors are located on dopami-
nergic neurons in the ventral tegmental area,205 where
they may modulate dopamine neuronal activity.206 In-
deed, it is likely that a predominant role of 5-HT2A recep-
tors in antipsychotic action is to modulate dopaminergic
tone, particularly along the mesocortical pathway.206–208
For example, clozapine, olanzapine, and ziprasidone, but
not haloperidol or risperidone, can preferentially augment
dopamine and norepinephrine release in the prefrontal cor-
tex relative to the subcortical areas.209 In rats, however, re-
peated administration of the selective 5-HT2A antagonist
M100907 can alter the activity of midbrain dopamine
neurons in rats, though there is disagreement as to whether
cortical dopamine levels are potentiated210 or inhibited.211
Thus, it has been hypothesized that the ultimate effect of
5-HT2A antagonists on dopaminergic neurotransmission
might be to stabilize it.208,212
Clinical studies with selective 5-HT2A receptor com-
pounds have also demonstrated a role of 5-HT2A receptors
in cognitive functioning in schizophrenia. For example, in
a study of 30 hospitalized patients with schizophrenia, ad-
ministration of mianserin, a 5-HT2A/2C and a2-adrenergic
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antagonist, improved scores on the Automated Neuropsy-
chological Assessment Metrics at 4 weeks, though no sig-
nificant improvement was found on the Wisconsin Card
SortingTest.213 Theseresults suggest that5-HT2A receptor
antagonism may improve cognitive function in schizo-
phrenia,214,215 though additional clinical studies are
needed. However,because nearly all approved atypicalan-
tipsychotic drugs have potent 5-HT2A antagonist actions,
it is unlikely that adding on a drug with potent 5-HT2A an-
tagonismwillprovideanysignificantboostingofcognition
in treated patients.212 The potential cognition-enhancing
effects resulting from 5-HT2A receptor antagonism with
the currently available atypical antipsychotics may be
masked by other drug actions, such as anticholinergic
effects, known to cause cognitive impairment.216
5-HT1A Receptors
5-HT1A receptors are densely concentrated in the hippo-
campus, lateral septum, amygdala, and cortical limbic
areas, as well as both the dorsal and median raphe nu-
clei.217,218 On raphe neurons, 5-HT1A receptors function
as somatic autoreceptors providing inhibitory feedback
control of 5-HT release.219 However, the highest concen-
trations of 5-HT1A receptors are on cortical and hippo-
campal pyramidal neurons220 suggesting a role of 5-HT1A
receptors in mediating cognitive functions. 5-HT1A recep-
tors on cortical pyramidal neurons are colocalized with
5-HT2A receptors,
221 though while 5-HT2A receptor acti-
vation is excitatory, 5-HT1A receptor activation inhibits
pyramidal neurons.222
Because they act on different locations of the receptors,
both 5-HT1A partial agonists and full antagonists have
shown a positive effect on cognitive activity in animals.223
Thus, 5-HT1A partial agonists, presumably acting on py-
ramidal neurons, improve cognition in animals, while 5-
HT1A antagonists also improve cognition, probably by
acting at the raphe autoreceptors.208,223 Indeed, atypical
antipsychotic drugs modestly enhance cognition, and sev-
eral atypical antipsychotic drugs have 5-HT1A partial ag-
onist actions (eg, aripiprazole, clozapine, olanzapine,
ziprasidone, quetiapine),224,225 while others are 5-HT1A
antagonists (eg, risperidone and sertindole).224 Preclinical
experiments also show that both 5-HT1A partial agonists
and antagonists can improve cognition. For example,
intraprefrontal infusion of 8-OH-DPAT, a nonselective
5-HT1A agonist, improved visual-spatial attention and
decreased impulsivity in rats,226 while WAY100635,
a 5-HT1A antagonist, blocked the deleterious effects of
MK-801 and NMDA antagonist in rats.227 Thus, the pre-
clinical literature is mixed regarding whether 5-HT1A ago-
nists or antagonists enhance cognition.
Clinicaldata in humansareequally mixed.For example,
activating 5-HT1A receptors with a single dose of tando-
spirone, a 5-HT1A partial agonist, diminished explicit
memory function228 in demented patients, though chronic
administration of tandospirone enhanced verbal memory
in patients with schizophrenia.229,230 Interestingly, the 5-
HT1A agonist NAE-086 actually induced hallucinations
and nightmares in normal individuals after repeated
doses,231 suggesting that 5-HT1A agonists may not be tol-
erated well in schizophrenic individuals. Taken together,
these results demonstrate that additional clinical studies
are needed but suggest that 5-HT1A receptors may need
tobedifferentlymodulatedtooptimallyenhancecognition
in various pathologic conditions (ie, dementia vs schizo-
phrenia) and that 5-HT1A partial agonists with a high level
of efficacy may present a significant risk of exacerbating
positive symptoms in schizophrenia.231
5-HT4 Receptors
Serotonin 5-HT4 receptors are found at high densities in
the hippocampus, frontal cortex, and amygdala, suggest-
ing a role of these receptors in cognitive functions.232,233
Indeed, 5-HT4 receptors have been shown to be markedly
decreased in patients with Alzheimer’s disease.234 In addi-
tion, 5-HT4 receptor agonists have shown promise in the
treatment of cognitive impairment by enhancing choliner-
gic transmission in the hippocampus.212,235 For example,
a 5-HT4 receptor partial agonist, SL65.0155, improved
learning and memory performance in chemically induced
rat model of amnesia,236 and this improvement may be
due in part to lengthening of the excitatory postsynaptic
potential in hippocampal CA1 pyramidal neurons.237
Interestingly,arecentstudyalsoshowedthattheactivation
of 5-HT4 receptors in a neuronal culture inhibited
the secretion of b-amyloid peptide and enhanced neu-
ronal survival.238 Thus, while 5-HT4 receptor–selective
agonists are mostly being studied for their role in the
treatment of Alzheimer’s disease, they may also be of
benefit in the treatment of the cognitive dysfunction
in schizophrenia.
5-HT6 Receptors
Several atypical antipsychotics, including clozapine and
olanzapine, and some tricyclic antidepressants, such as
amoxapine, amitriptyline, and clomipramine, were found
to have high affinity for 5-HT6 receptors
239–241 prompting
significant efforts to understand its possible role in schizo-
phrenia and other neuropsychiatric disorders. When anti-
sense oligonucleotides were used to decrease the level of 5-
HT6 receptor expression in rats, the rats exhibited an in-
creased number of yawns and stretches that could be
blocked by atropine, suggesting a role of the 5-HT6 recep-
tor in the control of cholinergic neurotransmission.242,243
In addition, the selective 5-HT6 receptor antagonist SB-
271046 has been shown to improve memory retention in
the water maze test of spatial learning and memory.244,245
Thus, it appears likely that 5-HT6 receptors may have an
important future role in the treatment of cognitive deficits
in neuropsychiatric illnesses such as Alzheimer’s disease
and schizophrenia.212
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5-HT7 Receptors
The 5-HT7 receptor exhibits a distinct distribution in the
central nervous system with relatively high levels in the
thalamus, hypothalamus, and hippocampus and lower
levels in the cortex and amygdala.246–248 In addition to
possible roles in regulating circadian rhythms and
sleep,249–251 5-HT7 receptors may also have an important
role in hippocampus-dependent functions such as learn-
ing and memory.252 For example, 5-HT7 receptor knock-
out mice have been found to exhibit a specific impairment
in contextual fear conditioning in which the animal learns
to associate the environment with an aversive stimulus,
a process generally believed to require the hippocam-
pus.253 Electrophysiological studies have also shown
that 5-HT7 receptor activation modulates the excitability
and intracellular signaling of pyramidal neurons in the
CA1 region of the hippocampus.254,255 Additionally, in
5-HT7 receptor knockout mice, there is a reduced ability
to induce long-term potentiation in the CA1 region of the
hippocampus.253 Together, these findings suggest an im-
portant role for the 5-HT7 receptor in hippocampus-de-
pendent functions, including learning and memory.252
Thus, selective 5-HT7 receptor activators might prove




The central noradrenergic system projects from the
locus ceruleus to the prefrontal cortex where a2-adren-
ergic receptors appear to play an important role in
cognitive functioning.256 Indeed, treatment with the
a2-adrenergic receptor agonists, clonidine and guanfa-
cine, has been shown to improve cognitive performance
without exacerbating positive symptoms in small
trials of patients with schizophrenia.257,258 In addition,
patients randomized to risperidone plus guanfacine
showed significant improvement on tasks of working
memory and attention compared with patients receiving
typical antipsychotics plus guanfacine.258 However, clo-
zapine and other atypicals have potent antagonist prop-
erties at a2-adrenergic receptors,
259 which may
contribute to the atypicality of atypicals by preferen-
tially enhancing dopaminergic transmission in the fron-
tal cortex over subcortical dopaminergic pathways.260
Indeed, combined treatment of a typical antipsychotic
with the highly selective a2-adrenergic receptor antago-
nist, idazoxan, has been reported to produce a profile of
antipsychotic activity similar to clozapine.261 Thus, as
a2-adrenergic receptor activity may be important in de-
veloping new drugs for schizophrenia that can improve
cognition, balancing a2-adrenergic receptor activity to
achieve both antipsychotic and procognitive efficacy
may be challenging.
GABAA Receptors
Appropriately synchronized GABA neurotransmission
in the dorsolateral prefrontal cortex is required for ade-
quate working memory,262 suggesting that impairments
in GABA-mediated inhibition could contribute to the
cognitive impairments in schizophrenia. Indeed, post-
mortem studies have shown reduced GABAergic trans-
mission in schizophrenia.263–265 In addition, recent
observations266,267 have noted decreases in messenger
RNA levels for glutamic acid decarboxylase 67, the syn-
thetic enzyme for GABA, selectively in the prefrontal
cortex of patients with schizophrenia. Interestingly, a re-
cent study revealed that GABA alterations in the dorso-
lateral prefrontal cortex of schizophrenic patients may be
restricted to certain cell classes, such as the chandelier
cells, which synchronize the activation of pyramidal neu-
rons via GABAA receptor subtypes.
268 Thus, the use of
new benzodiazepine-like agents—selective for the a2 sub-
unit of the GABAA receptor—in cognitive disorders
could be both interesting and revealing. Indeed, there is
evidence that reduced GABA neurotransmission in chan-
delier cells may be secondary to altered NMDA receptor
function and could represent a ‘‘final common pathway’’
of prefrontal dysfunction in schizophrenia.269 Thus, drugs
targeted to mitigate the disturbances in inhibition might be
particularly effective in improving cognitive performance
in schizophrenia. For example, positive allosteric modula-
tors selective for GABAA receptors containing a2 subunits
(eg, a GABAA a2-selective benzodiazepine) may improve
working memory function in schizophrenia.270 However,
drugs that directly activate a2-containing GABAA recep-
tors independent of the presence of GABA may disrupt the
critical synchronization of this circuit and impair working
memory.269 In addition, activation of GABAA receptors
containing other subunits (eg, a1 or a5), such as by cur-
rently available benzodiazepines, may impair cognitive
function. Indeed, a recent study in healthy volunteers
showed that, contrary to lorazepam, a GABAA a2/a3
subtype–selective partial agonist, TPA023, caused no
detectable memory impairment.271
As activation of GABAA receptors containing a5 sub-
units, such as by currently available benzodiazepines,
may impair cognitive function and cause sedation, inhib-
itors of these receptors have been hypothesized to en-
hance cognition. Indeed, functionally selective inverse
agonists at a5-containing GABAA receptors have been
demonstrated to enhance performance in animal models
of cognition,272–274 apparently without lowering the sei-
zure threshold as seen with nonselective GABAA inverse
agonists.274,275 In addition, a5 subunit knockout mice
demonstrate increased hippocampal activity due to the
release of tonic GABAergic inhibition.276 Thus, antago-
nists or inverse agonists at a5-containing GABAA recep-
tors may hold promise in the treatment of the cognitive
dysfunction in schizophrenia.
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Neurosteroids and Sigma Receptors
The sigma (r) receptor was initially designated as a sub-
type of opioid receptors277 but was later found to be a
distinct pharmacological entity due to lack of binding
of the classical opiate receptor antagonists naloxone
and naltrexone.278 Indeed, when the r1 receptor was iso-
lated and cloned, it was found to have no structural sim-
ilarity to the opioid receptors.279 The functions of these
receptors are poorly understood and endogenous ligands
have yet to be identified, though it has been proposed that
steroid hormones (eg, progesterone and testosterone),
drugs of abuse (eg, cocaine, heroin, PCP), and psychiatric
drugs (haloperidol, imipramine, and sertraline) may in-
teract with r receptors.280,281 In addition, it is well docu-
mented that r1 receptor ligands increase the NMDA
receptor response in the hippocampus,282–284 suggesting
a role in enhancing cognition. Indeed, r1 receptor ago-
nists can reverse the memory impairments induced by the
NMDA antagonists MK-801 in rodents.285
Neurosteroids, such as dehydroepiandrosterone
(DHEA) and allopregnanolone, have been implicated
in neuroprotection286–288 and enhancement of NMDA
receptor neurotransmission,287,289,290 possibly through
interaction with r1 receptors,290 suggesting therapeutic
potential for enhancing cognition in schizophrenia. Con-
sistent with the enhancement of NMDA neurotransmis-
sion, DHEA can enhance memory in rodents.291–294 In
humans, a double-blind study of DHEA as an adjunct
to antipsychotic treatment in chronic schizophrenic
patients with prominent negative symptoms suggests
some efficacy at improving negative symptoms, especially
in women,295 though further studies are needed. Thus,
neurosteroids may have therapeutic potential for improv-
ing the cognitive deficits observed in schizophrenia,
though long-term treatment with steroids is problematic.
In addition, while the contribution of r receptor agonism
to the actions of neurosteroids is not entirely known,
highly selective r receptor agonists are needed and
hold therapeutic promise.
Potential Future Targets
There are a number of additional largely theoretical phar-
macotherapeutic approaches for the treatment of cogni-
tion and schizophrenia. For example, significant progress
has been made in recent years on elucidating various sus-
ceptibility genes in schizophrenia, including dysbindin,
neuregulin 1, COMT, DISC1, and others.296 Interest-
ingly, many of these genes appear to be related to the con-
trol of synaptic plasticity and glutamate transmission
(particularly NMDA receptor function) and thus may al-
low for hypothesis-driven approaches for developing of
actual disease-modifying drugs for schizophrenia and
cognitive disorders.297 Another strategy involves the
role of neurotrophic factors in the pathophysiology of
schizophrenia and the theory that schizophrenia may in-
volve a neurodegenerative process.298 Neurotrophic fac-
tors, such as brain-derived neurotrophic factor, may play
a role in neuronal and glial differentiation, proliferation,
and regeneration and influence synaptic organization,
neurotransmitter synthesis, and the maintenance of syn-
aptic plasticity.299,300 Thus, strategies to enhance neuro-
trophic factor action may be able to prevent progression
of schizophrenia.
Altering neurotransmitter signaling by targeting intra-
cellular signaling cascades has long been suggested to be
a future approach to novel therapeutic agents.301 Though
there has been concern about the feasibility of this ap-
proach, lithium is a signal transduction modifier that
has been used safely for decades. Some targets being in-
vestigated include protein kinase C isoforms and glyco-
gen synthase kinase 3.302 In addition, subtype-selective
phosphodiesterase (PDE) inhibitors, particularly at
PDE10A, are actively being explored for the treatment
of various symptom domains in schizophrenia.303 An-
other interesting approach at the receptor level would
be developing ligands that differentially activate the var-
ious signaling pathways mediated by a single receptor,
a process termed ‘‘functional selectivity’’.304 Indeed,
functional selectivity has been described in serotonin,
opioid, dopamine, vasopressin, and adrenergic receptor
systems304 and may be initiated by different ligand-in-
duced conformational states, as shown for the b2-adren-
ergic receptor.305 Thus, the possibility of selecting or
designing novel ligands that differentially activate only
a subset of receptor functions is intriguing as an approach
to drug discovery that may optimize therapeutic action.
Conclusions
Cognitive dysfunction is a major feature of schizophrenia
that contributes significantly to the long-term functional
impairment that patients experience. While the past half-
century of antipsychotic development has had a profound
effect on the treatment of schizophrenia, the cognitive
deficits in schizophrenia have been insufficiently
addressed. Therefore, it is critical to continue the pursuit
of diverse molecular targets for discovering new pharma-
cotherapeutic agents for the treatment of schizophrenia.
For the past 20 years, psychopharmacologic research in
schizophrenia has aimed for the development of new an-
tipsychotic drugs with a more rapid onset of action,
lower risk of side effects, and improved efficacy in the
domains of negative and cognitive symptoms from a sin-
gle compound. Currently, however, it seems unlikely that
a single drug will have the desired effect across all these
domains, and thus, optimal treatment of schizophrenia
will likely rely on individualized polypharmacy and aug-
mentation strategies. The ultimate goal, of course, will be
the development of ‘‘cure therapeutics’’297 which will re-
quire significant advances in our understanding of the
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underlying pathophysiology of schizophrenia, highlight-
ing the need for continued basic research efforts at iden-
tifying and validating diverse and novel molecular
targets.
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